Walleye Capital
NTLA icon

Walleye Capital’s Intellia Therapeutics NTLA Stock Holding History

Walleye Capital’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$32K Sell
2,500
-9,900
-80% -$126K ﹤0.01% 3999
2025
Q4 		$111K Sell
12,400
-131,800
-91% -$1.81M ﹤0.01% 3825
2025
Q3 		$2.49M Sell
144,200
-72,400
-33% -$892K 0.01% 1412
2025
Q2 		$2.03M Buy
216,600
+178,400
+467% +$1.47M 0.01% 1502
2025
Q1 		$272K Buy
38,200
+32,700
+595% +$330K ﹤0.01% 3026
2024
Q4 		$64.1K Sell
5,500
-92,000
-94% -$1.44M ﹤0.01% 4291
2024
Q3 		$2M Sell
97,500
-24,100
-20% -$556K ﹤0.01% 1952
2024
Q2 		$2.72M Buy
121,600
+100,100
+466% +$2.38M ﹤0.01% 1823
2024
Q1 		$591K Sell
21,500
-4,300
-17% -$119K ﹤0.01% 3049
2023
Q4 		$787K Buy
25,800
+13,400
+108% +$385K ﹤0.01% 2571
2023
Q3 		$392K Buy
12,400
+5,800
+88% +$225K ﹤0.01% 2994
2023
Q2 		$269K Sell
6,600
-600
-8% -$24.3K ﹤0.01% 2890
2023
Q1 		$268K Buy
7,200
+5,100
+243% +$200K ﹤0.01% 2214
2022
Q4 		$73.3K Sell
2,100
-300
-13% -$14.3K ﹤0.01% 2443
2022
Q3 		$134K Buy
+2,400
New +$149K ﹤0.01% 2301
2020
Q2 		– Sell
-10,200
Closed -$125K – 859
2020
Q1 		$125K Sell
10,200
-12,200
-54% -$164K 0.03% 551
2019
Q4 		$329K Buy
22,400
+10,900
+95% +$152K 0.02% 878
2019
Q3 		$154K Sell
11,500
-2,000
-15% -$31.9K 0.01% 1298
2019
Q2 		$221K Buy
13,500
+8,000
+145% +$126K 0.02% 917
2019
Q1 		$94K Buy
+5,500
New +$82K 0.02% 1052

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Walleye Capital's NTLA Position: Q1 2026 in Review

Walleye Capital sold out of Intellia Therapeutics (NTLA) in Q1 2026, closing a stake of 6,580 shares — an estimated $83.8K sold.

Walleye Capital first reported a position in NTLA in Q3 2019 and held it in 17 quarters. The position peaked at $6.2M in Q4 2023. 302 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Walleye Capital reported no remaining Intellia Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Walleye Capital sold 6,580 Intellia Therapeutics shares in Q1 2026, an estimated $83.8K.
  • Walleye Capital first reported a position in Intellia Therapeutics in Q3 2019 and held it in 17 quarters.
  • Walleye Capital's Intellia Therapeutics position peaked at $6.2M in Q4 2023.
  • 302 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.